Skip to content
Clinical Trials – home

University Magna Graecia Of Catanzaro

Verified siteinfo

Italy Viale Tommaso Campanella 115, 88100 Catanzaro, Italy

  • 39 trials recruiting
  • Type 2 diabetes mellitus · Colitis ulcerative · Obesity
  • Adults and children

About Specializations

University Magna Graecia Of Catanzaro in Catanzaro, Italy specialises in clinical trials of conditions such as Type 2 diabetes mellitus, Colitis ulcerative, Obesity, Crohn's disease, and other specialisations. This site conducts important research.

Main research areas of the site

Cardiovascular Diseases

At University Magna Graecia Of Catanzaro, cardiovascular research focuses on heart failure, hypertension, and broader cardiovascular disease. These studies are designed to assess whether new treatment combinations can better reduce major heart-related events and improve outcomes in people with complex chronic conditions.

  • Evaluating new therapies for heart failure with impaired kidney function
  • Studying treatment options for hypertension linked with type 2 diabetes and cardiovascular disease
  • Measuring the ability of novel approaches to lower the risk of cardiovascular death and urgent heart-related hospital visits

This work combines cardiology, internal medicine, and metabolic disease research to explore better ways of managing high-risk patients.

Digestive System Diseases

Research in digestive system diseases is centered on ulcerative colitis, with an emphasis on understanding how long-term treatment may help people living with this chronic inflammatory condition. The trials aim to improve symptom control and support safer, more durable care strategies.

  • Assessing the safety and tolerability of a new treatment approach for ulcerative colitis
  • Supporting better long-term management of moderately to severely active inflammatory bowel disease
  • Exploring treatment options that may improve everyday disease control and quality of life

These studies reflect a strong interest in gastroenterology and chronic inflammation at the site.

Neoplasms

The oncology portfolio at this educational institution includes trials in breast cancer, especially HER2-positive breast cancer and HR+/HER2 breast cancer. The research is focused on testing new treatment combinations and comparing them with established care to improve tumor response and disease control.

  • Testing new treatment combinations for HER2-positive breast cancer
  • Evaluating therapies for locally advanced or metastatic breast cancer
  • Measuring whether novel regimens can improve pathologic response and extend progression-free survival

This area highlights active cancer research aimed at finding more effective options for patients with advanced disease.

Nervous System Diseases

Trials in nervous system diseases at the Department of Geriatria/Medicina Interna include studies in adult focal epilepsy. The goal is to determine whether newer add-on treatments can reduce seizure frequency while remaining well tolerated for long-term use.

  • Investigating better seizure control in focal epilepsy
  • Assessing the safety and tolerability of new adjunctive therapy options
  • Supporting improved management for adults already receiving standard anti-seizure medicines

These studies contribute to ongoing neurology research focused on practical improvements for people living with epilepsy.

Respiratory Tract Diseases

Respiratory research at University Magna Graecia Of Catanzaro includes work on acute respiratory distress syndrome, a serious condition that can require intensive care support. The trial activity is aimed at testing whether a new treatment can help improve breathing-related recovery and clinical outcomes.

  • Studying treatment strategies for acute respiratory distress syndrome
  • Evaluating whether a new therapy can increase ventilator-free days
  • Exploring approaches that may reduce the burden of severe respiratory failure

This field brings together critical care and pulmonary medicine research to address high-severity lung disease.

Kidney and Metabolic-Cardiovascular Research

Several trials at this site connect chronic kidney disease, type 2 diabetes, and cardiovascular disease, reflecting a strong focus on overlapping chronic illnesses. The purpose is to see whether new treatment combinations can slow kidney decline and reduce serious heart-related events.

  • Studying ways to slow progression of chronic kidney disease
  • Assessing therapies for people with type 2 diabetes and hypertension
  • Evaluating whether combined approaches can better protect kidney and heart health

This research area bridges nephrology, endocrinology, and cardiovascular medicine to address complex long-term disease management.

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Site location
Viale Tommaso Campanella 11588100 CatanzaroItaly
Recruiting now
39 trials
Conditions studied
74
Partner status
Verified site

More sites in CatanzaroItaly

Recruiting now

Ongoing trials

Clinical trials currently enrolling participants at this site.

Condition
Type of trial
Recruitment status
Quick filters

96 clinical trials

Obesity+2

Recruiting

Effect of zenagamtide on major adverse cardiovascular events in overweight or obese adults with established atherosclerotic cardiovascular disease

Investigational
Countries:ItalyItaly
  • Participants:18–64 years
  • Sponsor:Novo Nordisk A/S

Study of vicadrostat and empagliflozin combination in patients with type 2 diabetes, high blood pressure and cardiovascular disease

Registered drug
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:BI 690517
  • Sponsor:Boehringer Ingelheim Espana S.A.

Crohn's disease

Recruiting

Study of RO7790121 (afimkibart) for Treatment and Long-term Management in Adults with Moderate to Severe Crohn's Disease

Investigational
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:RO7790121
  • Sponsor:F. Hoffmann-La Roche AG

Study on the Safety of BHV-7000 for Adults with Hard-to-Treat Focal Onset Epilepsy

InvestigationalNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:BHV-7000
  • Sponsor:Biohaven Therapeutics Ltd.

Crohn's disease

Recruiting

Study on the Effects of MORF-057 for Adults with Moderate to Severe Crohn's Disease

Investigational
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:MORF-057
  • Sponsor:Morphic Therapeutic Inc.

Asthma

Recruiting

Study of Beclometasone Dipropionate in Patients with Asthma to Evaluate Disease Characteristics and Control

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Beclometasone Dipropionate
  • Sponsor:Sanofi-Aventis Recherche & Developpement

Phase 2 Randomized Double‑Blind Placebo‑Controlled Study of MH002 in Adults with Mild‑to‑Moderate Ulcerative Colitis Inadequately Controlled by 5‑ASA

Investigational
Countries:ItalyItaly
  • Participants:0–17 years · 18–64 years · 65+ years

Asthma

Recruiting

Efficacy and Safety of Depemokimab for Early Intervention in Adults and Adolescents with Type 2 Asthma at Risk of Exacerbations

Registered drug
Countries:ItalyItaly
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Depemokimab
  • Sponsor:Glaxosmithkline Research & Development Limited

Obesity

Recruiting

RO7795068 for Weight Loss in Adults With Obesity or Overweight and Type 2 Diabetes

Investigational
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Sponsor:F. Hoffmann-La Roche AG

Obesity

Recruiting

RO7795068 for Weight Loss in Adults With Obesity or Overweight Without Type 2 Diabetes

Investigational
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Sponsor:F. Hoffmann-La Roche AG

Treatment Study of Arsenic Trioxide, Tretinoin, and Gemtuzumab Ozogamicin for Children and Adolescents with Acute Promyelocytic Leukemia

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:0–17 years
  • Substances:Arsenic Trioxide
  • Sponsor:Associazione Italiana Ematologia Oncologia Pediatrica

A study to evaluate the effectiveness and safety of clemizole hydrochloride as an additional treatment for patients with Lennox-Gastaut syndrome

Investigational
Countries:ItalyItaly
  • Participants:0–17 years · 18–64 years
  • Substances:Clemizole Hydrochloride
  • Sponsor:Epygenix Therapeutics Inc.
Is this your site?

Join our network of research sites

Move up to Verified & featured: your own description, photos and phone number on this page, and top placement on every trial you run.

See the offer for sites
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.